Nuvilex to Present at the LD MICRO Invitational Conference on June 4, 2014
May 30 2014 - 9:00AM
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international
biotechnology company providing cell and gene therapy solutions for
the treatment of diseases, announced today that Kenneth L.
Waggoner, CEO and President, will present at the fourth annual LD
MICRO Invitational Conference at the Luxe Hotel in Los Angeles,
California on Wednesday, June 4th, 2014 at 4:00pm PDT. Nuvilex and
approximately one hundred other companies will be presenting and
conducting private meetings with potential investors over the
course of the day on June 4th.
About Nuvilex: Nuvilex, Inc. is a clinical
stage biotechnology company focused on developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live-cell encapsulation technology
known as Cell-in-a-Box®. This unique and patented technology will
be used as a platform upon which treatments for several types of
cancer, including advanced inoperable pancreatic cancer, and
diabetes are being built. Nuvilex's treatment for pancreatic cancer
involves the widely used anticancer prodrug ifosfamide, together
with encapsulated live cells, which convert ifosfamide into its
active or "cancer-killing" form. Nuvilex is also working towards
clinical trials associated with the symptoms of advanced pancreatic
cancer and other abdominal cancers. Nuvilex's subsidiary, Medical
Marijuana Sciences, Inc., is dedicated to the development of cancer
treatments based upon chemical constituents of marijuana known as
cannabinoids. To do so, it will examine ways to exploit the
benefits of Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of cannabinoids against cancers while minimizing or
eliminating the debilitating side effects usually associated with
cancer treatments. This provides Medical Marijuana Sciences a
unique opportunity to develop "green" approaches to fighting deadly
cancers, such as those of the pancreas, brain, breast and prostate,
that affect hundreds of thousands of individuals worldwide every
year.
About LD Micro
LD MICRO is an investment newsletter firm that focuses on
finding undervalued companies in the micro-cap space. Since 2002,
the firm has published an annual list of recommended stocks, as
well as comprehensive reports on select companies throughout the
year. The firm also hosts the LD MICRO Micro-Cap Growth Conference
for investors in December of each year. It is a non-registered
investment advisor. For more information, please contact
408-457-1042 or visit www.ldmicro.com.
Safe Harbor:
This press release may contain forward-looking statements
regarding Nuvilex and its future events and results that involve
inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to Nuvilex or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of Nuvilex, that could cause
actual results to differ materially from those set forth in the
forward-looking statements include Nuvilex's ability to continue as
a going concern, delays in clinical trials or flaws or defects
regarding its products, changes in relevant legislation or
regulatory requirements, uncertainty of protection of Nuvilex's
intellectual property and Nuvilex's continued ability to raise
capital. Nuvilex does not assume any obligation to update any of
these forward-looking statements.
More information about Nuvilex and Medical Marijuana Sciences
can be found at www.nuvilex.com and
www.medicalmarijuanasciences.com. It can also be obtained by
contacting Investor Relations.
CONTACT: Investor Relations Contacts:
Marlin Molinaro
Marmel Communications, LLC
Ph: 702.434.8692
mmolinarofc@aol.com
Dillon Heins
CorProminence, LLC
Ph: 218.839.9051
dillonh@corprominence.com